The Catalyst – Deconstructing the High-Profile Exits Recent announcements from major pharmaceutical players Novo Nordisk and Takeda regarding their withdrawal from cell therapy research and development have generated considerable industry discourse, fueling a narrative of a sector-wide retreat from this complex modality. However, a granular analysis of the strategic drivers behind these decisions reveals a … Continue reading Strategic Bifurcation in Cell Therapy: Why Big Pharma’s Recalibration Signals Maturity, Not Retreat